TABLE 1.
Top 30 significantly modulated canonical pathways (P < .01) related with commonly downregulated genes by BI‐D1870
| Ingenuity canonical pathways | −log (P‐value) | Gene | |
|---|---|---|---|
| 1 | B‐cell receptor signaling | 7.51 | APBB1IP, BCL2L1, BLNK, CD19, CD79B, CFL1, CREBBP, DAPP1, FCGR2B, GAB1, IKBKE, MEF2C, NFATC1, NFATC2, OCRL, PAX5, PIK3AP1, PIK3C2B, PIK3CG, PTPN6, RASSF5 |
| 2 | Communication between innate and adaptive immune cells | 4.50 | CCL3, CCR7, CD79B, CD86, TLR1, TLR10, TLR7, TLR9, TNFRSF13B, TNFRSF17 |
| 3 | Phospholipase C signaling | 4.27 | ARHGEF2, ARHGEF3, BLNK, CD79B, CREBBP, FCGR2B, GRAP2, HDAC7, HDAC9, ITGA4, LCK, MEF2C, MEF2D, NFATC1, NFATC2, PLD6, PRKD3, RHOBTB1, RHOH |
| 4 | Primary immunodeficiency signaling | 4.26 | BLNK, CD19, CIITA, LCK, RAG2, TNFRSF13B, UNG |
| 5 | Phagosome formation | 4.05 | FCGR2B, ITGA4, PIK3C2B, PIK3CG, PLCL2, PRKD3, RHOBTB1, RHOH, TLR1, TLR10, TLR7, TLR9 |
| 6 | PI3K signaling in B lymphocytes | 3.89 | BLK, BLNK, CD180, CD19, CD79B, DAPP1, FCGR2B, IKBKE, NFATC1, NFATC2, PIK3AP1, PIK3CG, PLCL2 |
| 7 | TREM1 signaling | 3.74 | CCL3, CD86, CIITA, FCGR2B, MYD88, TLR1, TLR10, TLR7, TLR9 |
| 8 | Chronic myeloid leukemia signaling | 3.71 | BCL2L1, E2F5, E2F8, HDAC7, HDAC9, IKBKE, MYC, PIK3C2B, PIK3CG, SMAD3, TGFBR2 |
| 9 | Protein kinase A signaling | 3.47 |
AKAP1, AKAP2, CREBBP, DUSP16, DUSP2, DUSP5, NFATC1, NFATC2, PDE4A, PDE4B, PDE8A, PDE9A, PLCL2, PLD6, PPP1R11, PRKD3, PTPN6, PTPN7, PTPN9, PTPRE, PTPRJ, SMAD3, TGFBR2, UBASH3B |
| 10 | B‐cell development | 3.18 | CD19, CD79B, CD86, RAG2, SPN |
| 11 | Cardiac hypertrophy signaling (enhanced) | 3.16 | CD70, CSF2RB, DLG1, HDAC7, HDAC9, IFNLR1, IKBKE, IL21R, IL27RA, ITGA4, MAP3K20, MEF2C, MEF2D, MYC, NFATC1, NFATC2, PDE4A, PDE4B, PDE8A, PDE9A, PIK3C2B, PIK3CG, PLCL2, PLD6, PRKD3, TGFBR2, WNT10A |
| 12 | Molecular mechanisms of cancer | 3.08 | ARHGEF2, ARHGEF3, BCL2, BCL2L1, BIRC3, CASP10, CREBBP, E2F5, E2F8, GAB1, ITGA4, MYC, PIK3C2B, PIK3CG, PRKD3, RASGRP1, RHOBTB1, RHOH, SMAD1, SMAD3, SMAD6, TGFBR2, WNT10A |
| 13 | Death receptor signaling | 2.96 | BCL2, BIRC3, CASP10, DFFB, IKBKE, PARP12, PARP8, PARP9, TNFRSF10A |
| 14 | Pancreatic adenocarcinoma signaling | 2.90 | BCL2, BCL2L1, E2F5, E2F8, HBEGF, PIK3C2B, PIK3CG, PLD6, SMAD3, TGFBR2 |
| 15 | Altered T cell and B cell signaling in rheumatoid arthritis | 2.73 | CD79B, CD86, TLR1, TLR10, TLR7, TLR9, TNFRSF13B, TNFRSF17 |
| 16 | Nur77 signaling in T lymphocytes | 2.60 | BCL2, CD86, HDAC9, MEF2D, NFATC1, NR4A1 |
| 17 | Prolactin signaling | 2.59 | CREBBP, IRF1, MYC, NMI, PIK3C2B, PIK3CG, PRKD3, SOCS2 |
| 18 | Cell cycle: G1/S checkpoint regulation | 2.57 | E2F5, E2F8, HDAC7, HDAC9, MYC, PAK1IP1, SMAD3 |
| 19 | T cell receptor signaling | 2.52 | GRAP2, IKBKE, LCK, NFATC1, NFATC2, PIK3C2B, PIK3CG, PTPN7, RASGRP1 |
| 20 | Role of pattern recognition receptors in recognition of bacteria and viruses | 2.48 | CD70, EIF2AK2, IFIH1, MYD88, OAS1, PIK3C2B, PIK3CG, PRKD3, TLR1, TLR7, TLR9 |
| 21 | Purine nucleotides de novo biosynthesis II | 2.47 | ADSS, GART, IMPDH1 |
| 22 | Role of NFAT in regulation of the immune response | 2.40 | BLNK, CD79B, CD86, FCGR2B, IKBKE, LCK, MEF2C, MEF2D, NFATC1, NFATC2, PIK3C2B, PIK3CG |
| 23 | NF‐κB signaling | 2.36 | CREBBP, EIF2AK2, LCK, MYD88, PIK3C2B, PIK3CG, TGFBR2, TLR1, TLR10, TLR7, TLR9, TNFRSF17 |
| 24 | CD28 signaling in T helper cells | 2.31 | CD86, GRAP2, IKBKE, LCK, NFATC1, NFATC2, PIK3C2B, PIK3CG, PTPN6 |
| 25 | April‐mediated signaling | 2.29 | IKBKE, NFATC1, NFATC2, TNFRSF13B, TNFRSF17 |
| 26 | STAT3 pathway | 2.23 | BCL2, CSF2RB, IFNLR1, IL21R, IL27RA, MAP3K20, MYC, PTPN6, SOCS2, TGFBR2 |
| 27 | B‐cell activating factor signaling | 2.20 | IKBKE, NFATC1, NFATC2, TNFRSF13B, TNFRSF17 |
| 28 | Th1 and Th2 activation pathway | 2.18 | BHLHE41, CD86, IKZF1, IL27RA, IRF1, NFATC1, NFATC2, PIK3C2B, PIK3CG, S1PR1, TGFBR2 |
| 29 | tRNA splicing | 2.15 | PDE4A, PDE4B, PDE8A, PDE9A, PLD6 |
| 30 | Systemic lupus erythematosus signaling | 2.15 | CD72, CD79B, CD86, FCGR2B, LCK, NFATC1, NFATC2, PIK3C2B, PIK3CG, PTPN6, TLR7, TLR9 |